44 results about "Herpes virus" patented technology

The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

The present invention relates to a novel crystalline form of a helicase-primase inhibitor compound, and to pharmaceutical compositions comprising the novel crystalline form, to methods of production of the novel crystalline form, to the crystalline form in medicine and for use in the treatment of herpes viral infections.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

A patch composition for targeting herpes virus comprising the following ingredients: a patch base, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, peppermint, sodium saccharin, naringin, wind wheel grass extract, xanthan gum, polyethylene glycol-8, calcium carbonate, hydroxyethyl cellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, strontium chloride hexahydrate, tranexamic acid, two-faced needle extract, sodium monofluorophosphate, sea salt, potassium nitrate, sodium chloride, and purified water q.s.

The present application relates to an avian cell line capable of supporting viral growth of Marek's Disease Virus (MDV), including Herpes Virus of Turkeys (HVT), methods of producing such cell lines, and therapeutic uses of the cell lines and resulting vaccines.

The present application relates to the fields of biotechnology and agricultural fishery, and discloses application of star anise water extract in preparation of an inhibitor of CyHV-2, and the technical scheme finds that the star anise water extract can effectively inhibit the infection and replication of CyHV-2 virus in GiCF cells. The present application firstly applies the star anise water extract to prevent and treat the infection of CyHV-2 (CyHV-2), thereby providing a new treatment scheme for CyHV-2 virus. The star anise water extract can effectively reduce the copy number of CyHV-2 virus, and the star anise water extract can be used to prepare a medicine for preventing and treating the infection of CyHV-2, and a medicine for treating viral hematopoietic organ necrosis disease of fish.

This fatigue estimation device (100) comprises: a fatigue estimation model (12) constructed in advance on the basis of data including a relationship between a physiological quantity outside an activity period of a person and the amount of human herpesvirus outside the activity period, the fatigue estimation model (12) being capable of outputting a fatigue degree estimated from the corresponding amount of human herpesvirus in response to an input of biometric information; a physiological quantity measurement unit (20) for measuring a physiological quantity of a subject (user (99)); and a fatigue estimation unit (10) for outputting the fatigue degree of the subject on the basis of the measured physiological quantity by using the fatigue estimation model (12).

This invention belongs to the field of molecular diagnostics, specifically relating to biomarkers for the diagnosis of herpes simplex keratitis (HSK) and their applications. This invention is the first to demonstrate that C1QA and FCERT1G are specific and reliable inflammation-related biomarkers for HSK. Diagnostic and assessment methods based on these biomarkers can provide crucial molecular evidence for the early detection, accurate diagnosis, objective severity grading, and personalized treatment of HSK. Simultaneously, this invention reveals the potential roles of FCERT1G and C1QA in HSK and provides new ideas for targeted therapy of this disease, particularly the application of goserelin as an inflammation modulator, offering a new direction for HSK treatment.

Provided are human herpesvirus affinity ligands and related compositions including affinity resins.

This invention belongs to the field of natural and chemical medicine technology, and discloses two types of *Symplocos edulis* (a type of plant) from the genus *Symplocos*. Bag Philippians The resorcinol compounds were isolated from [the organism]. The structures of the resorcinol compounds are shown in formula (I) or formula (II). The resorcinol compounds of this invention exhibit significant inhibitory effects on respiratory syncytial virus (RSV) and herpes simplex virus (HSV) even at low concentrations, and show low cytotoxicity and high selectivity, demonstrating promising applications in antiviral drugs and medications for treating diseases caused by RSV and HSV infections.

The application relates to methods and intermediates for synthesizing the thiazole derivative Coumpound (1) useful in treating and / or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection.

Disclosed are topical compositions comprising hyaluronic acid or salts thereof and iota-carrageenan, preferably in a mucoadhesive matrix containing ascorbyl palmitate and choline alfoscerate. The compositions according to the invention are useful for topical treatment of Herpesvirus infections.

Compositions and methods discussed herein provide for treatment or prevention of a disease or disorder, or its symptoms, using a modified herpes simplex virus (mHSV) vector comprising at least two transgenes, wherein at least a first transgene encoding a gene-editing system, gene-deletion system, or bridge-editing system is expressed to knock out or delete an endogenous target gene and at least a second transgene encoding a corrected copy of the endogenous targeted gene, wherein the gene product of the second transgene replaces the gene product of the endogenous target gene.

This invention belongs to the field of viral genetic engineering technology and discloses a bovine herpesvirus type 1 (BHV-1) with three gene deletions, its construction method, and its applications. Using a Fosmid library, four myxovirus rescue combinations were screened. FosBHV-1-b-ΔTK-mCherry and FosBHV-1-d-ΔgEct / US9-eGFP were obtained through Red / ET and Gateway methods. These were then combined with FosBHV-1-a and FosBHV-1-c to construct an infectious cloning platform for recombinant BHV-1 with the TK / gEct / US9 three-gene deletions, rescuing recombinant viruses carrying tracer genes. This method has high recombination efficiency, and the cloning platform can efficiently construct BHV-1 gene-deleted strains. The immunogenicity of the deleted strains is comparable to that of wild-type viruses, with good safety, providing an efficient technical means for the development of BHV-1 attenuated vaccines and bovine disease live vector vaccines.

This invention provides a nanobody targeting carp herpesvirus type II and its application. The amino acid sequence of the nanobody is shown in SEQ ID NO. 1-6. The method includes immunizing alpacas with inactivated carp herpesvirus type II, collecting peripheral blood from the immunized alpacas and separating lymphocytes, and extracting total RNA; synthesizing cDNA by reverse transcription, and amplifying the gene fragment encoding the nanobody; ligating it into the pComb3xss vector, and then transforming it into competent cells to construct a nanobody phage display library; enriching and panning the inactivated virus as a coating antigen to obtain specifically binding phage particles; transforming the selected positive clones into host bacteria for induced expression; and obtaining the anti-carp herpesvirus type II nanobody after separation and purification. This invention aims to provide a carp herpesvirus type II nanobody that is low in expression cost and difficulty, has a stable source, can effectively bind to carp herpesvirus type II, and specifically achieves immunoassay of carp herpesvirus type II.

The application discloses a use of hyperoside in resisting equid herpesvirus 8 (EHV-8) infection. Through qPCR, Western Blot and other experimental techniques, it is revealed on multiple levels that the hyperoside can significantly inhibit the replication of EHV-8, and the mechanism of the hyperoside in resisting the EHV-8 infection is clarified from the aspect of blocking the internalization of the EHV-8, so that the hyperoside can be applied in preparing an anti-EHV-8 medicine.

The application discloses a feline panleukopenia virus, feline herpes virus and feline calicivirus yolk antibody preparation and a preparation method and application thereof. The feline triple yolk antibody preparation comprises a core material, and the core material comprises feline calicivirus yolk antibody, feline panleukopenia virus yolk antibody, feline herpes virus type 1 yolk antibody and probiotics. The application can produce specific neutralization to feline calicivirus, feline panleukopenia virus and feline herpes virus type 1, significantly reduces the infection rate and the severity of clinical symptoms, is stably released in the gastrointestinal tract after oral administration, the antibody activity retention rate is more than 90%, the probiotics synergistically regulate intestinal microecology, enhance the immune response of the body and improve the overall protection efficiency.

The application relates to methods and intermediates for synthesizing the thiazole derivative Compound 1 useful in treating and / or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection. (I)

This invention discloses a primer, kit, and application for isothermal amplification detection of feline gamma herpesvirus type 1 (FHV-1), belonging to the field of nucleic acid detection technology. The invention provides primers for detecting FHV-1, comprising one outer primer and one inner primer. The nucleotide sequence of the upstream primer F3 of the outer primer is shown in SEQ ID NO. 2; the nucleotide sequence of the downstream primer B3 of the outer primer is shown in SEQ ID NO. 3; the nucleotide sequence of the upstream primer FIP of the inner primer is shown in SEQ ID NO. 4; and the nucleotide sequence of the downstream primer BIP of the inner primer is shown in SEQ ID NO. 5. The loop-mediated isothermal amplification detection method for FHV established using these primers is rapid, efficient, highly sensitive, and specific. It reduces the diagnostic complexity caused by co-infection, has low equipment dependence, is suitable for field applications, and enables efficient monitoring of viral shedding levels.

Compounds, methods, and compositions for treating or preventing viral infections using nucleoside compounds. The nucleoside compounds have increased antiviral activity potential with the result of inhibiting at least one of flaviviruses, herpesviruses, polyomaviruses, alphaviruses, enteroviruses, filoviruses matonaviruses, phenuiviruses, Hepatitis B virus, and / or coronaviruses.

The present application relates to the fields of biotechnology and agricultural fishery, and discloses application of curcumin in preparation of an inhibitor of CyHV-2, and finds that curcumin can effectively inhibit the infection and replication of CyHV-2 virus in GiCF cells.The present application first applies curcumin to the prevention and treatment of CyHV-2 infection, thereby providing a new treatment scheme for CyHV-2 virus.Curcumin can effectively reduce the copy number of CyHV-2 virus, and curcumin can be used to prepare a drug for preventing and treating CyHV-2 infection, and a drug for treating viral hematopoietic organ necrosis in fish.

(A first) anti-HSV antibody or an antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, wherein the antibody comprises complementarity-determining regions V each containing the sequences defined in the claims H CDR1, V H CDR3, V L CDR1, V L CDR2, and V L CDR3, and wherein the antibody or its antigen-binding fragment has a maximum dissociation rate k -4 s -1 of at most 5.0 x 10 -4 s -1 preferably at most 1.0 x 10 -5 s -1 most preferably at most 2.9 x 10 -5 s -1 is described. Further, (A) the (first) anti-HSV antibody or its antigen-binding fragment, and (B) a second anti-HSV antibody or its antigen-binding fragment that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, wherein the antibody comprises complementarity-determining regions V each containing the sequences defined in the claims dis CDR1, V H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V LA combination of a second anti-HSV antibody or its antigen-binding fragment is described, comprising CDR3, wherein the second antibody has a dissociation constant Kd of up to 40 nM, preferably up to 30 nM, more preferably up to 20 nM, even more preferably up to 15 nM, up to 13 nM, and up to 10 nM. Furthermore, a pharmaceutical composition is described comprising an effective amount of the anti-HSV antibody or its antigen-binding fragment, or the combination of the antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the anti-HSV antibody or its antigen-binding fragment or the combination of the antibodies is described for use in a method for the prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, (A) V, which is the complementarity-determining region of the first antibody described above. H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V L (B) The first binding domain containing CDR3 and (B) the complementarity determining region of the second antibody described above. H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V L A bispecific antibody that binds to glycoprotein B(gB) of HSV-1 and / or HSV-2, comprising a second binding domain containing CDR3, with a maximum capacity of 5.0 x 10⁻¹⁴. -4 s -1 Preferably a maximum of 1.0 x 10 -4 s -1 , up to 5.0x10 -5 s -1 Most preferably a maximum of 2.9 x 10 -5 s -1 A bispecific antibody having a low dissociation rate of kdis is described. Finally, a triplicate antibody is described that includes a third binding domain in addition to the first and second binding domains described for the bispecific antibody.

The present invention relates to a fish pathogenic virus, provisionally called Labeo cichlid herpesvirus (LCHV), which causes a disease in fish, cell cultures comprising said virus, DNA fragments of said virus and the corresponding proteins, vaccines based on said virus, DNA and / or proteins and antibodies reacting with said virus and diagnostic test kits for detecting said virus.

This invention discloses a replication-deficient recombinant rabies virus chimerically expressing feline herpesvirus type I protein and its applications. It belongs to the field of biomedical technology. The purpose of this invention is to provide a genetically engineered vaccine for feline infectious rhinotracheitis. This invention provides a replication-deficient recombinant rabies virus chimerically expressing feline herpesvirus type I protein, using plasmid combination 1 or plasmid combination 2 to rescue rabies virus strains; plasmid combination 1 is shown below: pD-N, pD-P, pD-G, pD-L, and pD-SRV9-△G-gB; plasmid combination 2 is shown below: pD-N, pD-P, pD-G, pD-L, and pD-SRV9-△G-gD. The goal is to develop a safe and effective novel vaccine.

The application provides use of indole-3-propionic acid (IPA) in anti-herpes virus and a medicine and a feed additive containing the indole-3-propionic acid, and belongs to the technical field of biological medicine. The application provides application of the IPA in preparation of an antiviral agent for herpes virus, and after intervention of the IPA, the survival rate of infected mice can be obviously improved. Furthermore, after intervention of the IPA, the index of the parenchyma organs of the mice is obviously lower than that of a positive infection group; the level of inflammatory factors in each organ in the later infection stage is obviously improved, and the intestinal barrier is obviously improved; the intervention of the IPA can also obviously reduce the transcription level of PRV related genes. The IPA has the function of inhibiting pseudorabies virus replication, and can be used for preparation of a medicine for preventing and / or treating diseases caused by herpes virus infection or a corresponding feed additive.

Disclosed herein is a method for predicting prognosis of a subject being with a cancer, such as a malignant glioma, being treated with an oncolytic herpes simplex virus (oHSV) that involves assaying a sample from the subject for Acyl-CoA-binding protein (ACBP) levels, wherein an elevated level of ACBP compared to a control is an indication of a poor prognosis. Also disclosed herein is a method for treating a cancer, such as a malignant glioma, in a subject that involves administering to the subject an effective amount of an oncolytic herpes simplex virus (oHSV) in combination with a glioma Bmi1 inhibitor or a fatty acid oxidation (FAO) inhibitor optionally followed by one or more immune checkpoint inhibitors.